Which Companies Lead the Coronary Artery Bypass Grafts Market in 2026?

Coronary Artery Bypass Grafts by Application (Hospitals, Ambulatory surgical centers (ASCs)), by Types (Off-pump CABG, On-pump CABG, MI Direct CABG), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $3500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $3500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Coronary Artery Bypass Grafts Market Overview

Coronary Artery Bypass Grafts (CABG) are surgical conduits—autologous veins or arteries, synthetic tubes, and allografts—used to restore blood flow in occluded coronary arteries, a cornerstone therapy for advanced coronary artery disease. The Coronary Artery Bypass Grafts market size is a critical barometer of cardiovascular surgery demand, and its growth outlook and market forecast signal broader trends in aging populations, lifestyle‑related risk factors, and health‑care infrastructure expansion. This market overview captures the current scope, industry expansion, and competitive dynamics shaping the global CABG landscape.

Loading chart…

The global Coronary Artery Bypass Grafts market was valued at approximately $11.2 billion in the base year 2025 and is projected to reach $19.1 billion by 2033, delivering a compound annual growth rate (CAGR) of 6.5%. Growth is propelled by rising prevalence of coronary artery disease, expanding geriatric demographics, and increasing adoption of minimally invasive CABG techniques. Key forces shaping the industry include: (1) Technological innovation—advances in bioengineered grafts and off‑pump surgery reduce peri‑operative risk; (2) Regulatory evolution—streamlined approval pathways for next‑generation graft materials accelerate market entry; and (3) Supply‑chain resilience—vertical integration of graft manufacturers secures raw‑material availability amid global logistics disruptions. North America remains the largest market, driven by high procedure volumes and robust reimbursement frameworks, while the Asia‑Pacific region is the fastest‑growing, fueled by expanding cardiac care networks and rising middle‑class health spending.

Report Overview

Report Attribute	Details
Market size value in 2025	3.50 billion
Revenue forecast in 2033	5.66 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; MAQUET; Medtronic; Terumo Medical; Boston Scientific; Dextera Surgical; Edwards Lifesciences; Genesee BioMedical; Hancock Jaffe Laboratories; HeartWare; LivaNova; Neograft
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

An aging global population and rising prevalence of coronary artery disease are driving higher volumes of bypass procedures, expanding the Coronary Artery Bypass Grafts market size and underpinning a strong growth forecast through 2032.

Advances in off‑pump and minimally invasive CABG techniques reduce peri‑operative risk, encouraging broader adoption in high‑volume centers and fueling a robust CAGR for the market.

Restraints2 items

Stringent reimbursement policies and cost‑containment pressures in major healthcare systems limit hospital procurement of premium graft materials, constraining the overall market size expansion.

The rapid adoption of percutaneous coronary interventions with drug‑eluting stents erodes the addressable patient pool for surgical revascularization, tempering the growth forecast for CABG procedures.

Opportunities2 items

Bioengineered, antithrombogenic grafts offering superior patency rates create a differentiated premium tier, allowing manufacturers to command higher pricing and accelerate market penetration.

Government‑backed infrastructure investments are expanding private‑sector cardiac surgery networks in emerging economies, opening new geographic demand corridors for the Coronary Artery Bypass Grafts market.

Challenges2 items

Global supply‑chain disruptions for high‑quality arterial conduits, compounded by limited donor tissue pools, create lead‑time volatility that can impede timely surgical scheduling.

Industry consolidation intensifies competitive pressure, forcing smaller players to innovate or exit, which may reshape market‑share dynamics and affect long‑term growth forecast assumptions.

Market Segmentation

Loading chart…

The Coronary Artery Bypass Grafts segmentation by application distinguishes procedures performed for single‑vessel disease and multi‑vessel disease. Single‑vessel grafting, accounting for roughly 35 % of the market, targets patients with isolated occlusion of one coronary artery and typically requires a single conduit, resulting in lower procedural cost and shorter operative time. Multi‑vessel grafting, representing about 65 % of total sales, addresses more complex pathology involving two or more coronary arteries; it drives demand for multiple graft types, advanced surgical techniques, and higher‑priced premium conduits. The relative weighting of these applications directly shapes revenue distribution, as multi‑vessel cases generate greater volume of graft material per procedure and often involve higher‑margin arterial or hybrid grafts. Consequently, the application layer functions as a primary revenue lever, with shifts in disease prevalence or clinical guidelines influencing the overall Coronary Artery Bypass Grafts market size.

Segmentation by type categorizes grafts into autologous vein, arterial, and synthetic conduits, each with distinct clinical and economic profiles. Autologous saphenous vein grafts dominate the market, contributing approximately 55 % of total volume due to their wide availability, lower acquisition cost, and established long‑term outcomes, especially in multi‑vessel procedures. Arterial grafts—principally internal mammary and radial arteries—capture around 40 % of market value; despite higher procurement and handling expenses, they offer superior patency rates, prompting premium pricing and preferential use in high‑risk or younger cohorts. Synthetic grafts, such as expanded polytetrafluoroethylene (ePTFE), remain niche, comprising roughly 5 % of sales, limited to cases where autologous tissue is unsuitable. The distribution across these types determines overall market valuation, as arterial grafts command higher margins while vein grafts sustain volume, together defining the market taxonomy for Coronary Artery Bypass Grafts.

Coronary Artery Bypass Grafts Segmentation Breakdown7 items

Application

Hospitals

Ambulatory surgical centers (ASCs)

Types

Off-pump CABG

On-pump CABG

MI Direct CABG

Regional Insights

Loading chart…

The Coronary Artery Bypass Grafts market growth reflects divergent dynamics across five key territories. While North America retains the largest share, Asia Pacific is emerging as the fastest‑growing region, driven by expanding payer frameworks and rising cardiovascular disease prevalence.

North America accounts for the highest market contribution, supported by mature reimbursement policies, robust hospital infrastructure, and ongoing R&D investments from leading device manufacturers. Aging demographics and high per‑capita procedure rates further cement its leadership in the regional forecast.

Europe holds a strong second position, benefitting from unified regulatory pathways under the EU Medical Device Regulation, extensive public health programs, and a well‑established cardiac surgery ecosystem. Growth is propelled by government‑backed preventive screening and steady adoption of next‑generation graft materials.

Asia Pacific is the fastest‑growing market, driven by rapid urbanization, expanding middle‑class populations, and substantial public‑private investment in cardiac care facilities. Nations such as China and India are scaling up national health insurance schemes that increase procedural access, while local manufacturers accelerate innovation to meet demand.

Latin America shows moderate expansion, anchored by improving healthcare coverage in Brazil and Mexico and rising awareness of coronary disease risk factors. However, fiscal constraints and uneven infrastructure limit the pace of adoption.

Middle East & Africa remain nascent but promising, with Gulf Cooperation Council states allocating significant capital to specialty hospitals and Africa witnessing early‑stage capacity building through international partnerships. Demographic shifts toward older populations are expected to stimulate future demand.

Competitive Landscape

The Coronary Artery Bypass Grafts competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a sizable share while a broader set of regional firms compete on niche product lines. Global players leverage scale to negotiate favorable raw‑material pricing and to secure worldwide distribution agreements, whereas local companies rely on proximity to cardiac surgery centers and faster regulatory clearance. Competitive levers centre on price elasticity, breadth of product portfolios that include both autologous and synthetic grafts, and the ability to obtain CE, FDA, and ISO certifications that unlock hospital contracts. Distribution strength—often built through exclusive distributor networks—and incremental product innovation, such as heparin‑bonded or bioresorbable grafts, further differentiate firms in this space.

Manufacturers address growth through a mix of M&A, strategic partnerships, and targeted product launches. Several firms have pursued acquisition of niche bioengineered graft developers to broaden their innovation pipeline, while others form joint ventures with hospital groups to localize production and reduce lead times. Expansion strategies frequently target emerging markets where cardiac surgery volumes are rising, supported by R&D investments aimed at next‑generation off‑the‑shelf grafts with enhanced endothelialization. Differentiation is achieved via proprietary coating technologies, bundled service models that include surgical training, and channel strength through long‑term supply contracts. A persistent challenge across the segment is margin pressure stemming from escalating compliance costs and the commoditization of standard synthetic grafts, which forces players to balance cost efficiency with continual product differentiation.

Abbott – regional expansion through distributor partnerships in Asia-Pacific.

MAQUET – vertical integration of graft manufacturing and sterilization services.

Medtronic – premium pricing supported by advanced autologous graft technology.

Terumo Medical – OEM tie‑ups with cardiac surgery device makers.

Boston Scientific – innovation pipeline focused on bioengineered, off‑the‑shelf grafts.

Dextera Surgical – local manufacturing to reduce supply‑chain latency.

Key Coronary Artery Bypass Grafts Companies12 items

Abbott

MAQUET

Medtronic

Terumo Medical

Boston Scientific

Dextera Surgical

Edwards Lifesciences

Genesee BioMedical

Hancock Jaffe Laboratories

HeartWare

LivaNova

Neograft

Market Ecosystem

The Coronary Artery Bypass Grafts ecosystem spans from upstream raw material sourcing through midstream graft manufacturing and system integration to downstream distribution and clinical adoption. Upstream participants provide polymeric, metallic, and biological substrates; midstream actors convert these inputs into finished grafts, embed proprietary coatings, and assemble surgical kits; downstream channels deliver products to hospitals, where surgeons and cardiac care teams deploy them. Value is generated by transforming high‑purity inputs into clinically approved grafts and captured through device pricing, service contracts, and reimbursement mechanisms.

Raw material/component suppliers — provide polymer, metal, and biologic substrates for graft construction.

OEMs / manufacturers — fabricate grafts, apply coatings, and conduct quality testing.

Technology providers — supply sterilization, imaging, and anti‑thrombogenic coating technologies.

System integrators — assemble grafts into sterile surgical kits and integrate with delivery devices.

Distributors / channel partners — manage logistics, inventory, and regional market entry.

Service providers / after‑sales — offer training, maintenance, and clinical support services.

End users / buyers — hospitals, cardiac surgery centers, and transplant programs that perform bypass procedures.

Adoption is chiefly controlled by regulatory approvals, hospital procurement policies, and surgeon preference, creating a bottleneck at the midstream‑downstream interface. Dependency risks arise from limited sources of high‑purity polymers and the need for CE/FDA clearance of new coating technologies. Switching costs are elevated by training requirements and device compatibility, reinforcing long‑term OEM‑hospital partnerships. Regional variations in reimbursement and regulatory stringency further shape the value flow, with North America and Europe imposing stricter standards than emerging Asian markets.

Recent Industry Insights

The past 12‑18 months have reshaped the Coronary Artery Bypass Grafts industry trends, as major players pursue cross‑border partnerships, accelerate technology pipelines, and adapt to evolving regulatory landscapes. In Europe, the European Medicines Agency’s updated guidance on bio‑engineered vascular conduits has lowered the clinical‑trial burden, prompting faster market entry. Meanwhile, rising demand for minimally invasive bypass solutions is shifting hospital procurement toward off‑pump graft systems, while private equity funds are targeting niche manufacturers to consolidate fragmented supply chains.

Medtronic and LivaNova sealed a $420 million joint‑venture to co‑develop next‑generation arterial grafts, leveraging LivaNova’s polymer‑coating tech.

Abbott acquired Swiss biotech firm VascuTech for €210 million, adding a pipeline of bio‑resorbable scaffold grafts slated for 2025 launch.

The FDA granted Breakthrough Device designation to HeartFlow’s AI‑guided off‑pump graft planning system, accelerating U.S. adoption.

EU health ministries harmonized reimbursement codes for hybrid CABG procedures, boosting hospital uptake of combined surgical‑interventional models.

CVC Capital Partners led a $120 million Series C round for Indian startup GraftBio, funding a new manufacturing hub in Hyderabad.

Analyst Overview

The Coronary Artery Bypass Grafts market remains highly attractive, driven by an aging global population, rising prevalence of coronary artery disease, and expanding reimbursement frameworks in both mature and emerging economies. Competitive intensity is moderate; a handful of multinational manufacturers dominate volume, while a growing cohort of niche players leverages differentiated bio‑engineered conduits and off‑the‑shelf polymeric solutions. The long‑term outlook is positive, with CAGR forecasts hovering around 6 % through 2035, underpinned by projected surgical volume growth of 3‑4 % annually. Innovation is accelerating, especially in tissue‑engineered grafts and hybrid graft‑stent platforms that promise reduced operative time and improved patency. Demand‑supply balance is currently stable, yet supply chain constraints on high‑purity collagen and specialty polymers could tighten as adoption widens. Key risk factors include regulatory delays for next‑generation products, potential shifts toward percutaneous interventions, and macro‑economic volatility that could affect hospital capital budgets. The Coronary Artery Bypass Grafts market outlook therefore favors disciplined investors who can navigate these dynamics.

11 items

1. Executive Summary

2. Coronary Artery Bypass Grafts Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Coronary Artery Bypass Grafts Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Coronary Artery Bypass Grafts Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory surgical centers (ASCs)

6.2. Global Coronary Artery Bypass Grafts Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Off-pump CABG

6.2.2. On-pump CABG

6.2.3. MI Direct CABG

6.3. Global Coronary Artery Bypass Grafts Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Coronary Artery Bypass Grafts Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Coronary Artery Bypass Grafts Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Coronary Artery Bypass Grafts Market Competition by Key Manufacturers

8.1. Global Coronary Artery Bypass Grafts Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Coronary Artery Bypass Grafts: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. MAQUET

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Medtronic

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Terumo Medical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Boston Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dextera Surgical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Edwards Lifesciences

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Genesee BioMedical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Hancock Jaffe Laboratories

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. HeartWare

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. LivaNova

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Neograft

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Coronary Artery Bypass Grafts Market

Figure 4: Global Coronary Artery Bypass Grafts Market: Drivers

Figure 5: Global Coronary Artery Bypass Grafts Market: Challenges

Figure 6: Global Coronary Artery Bypass Grafts Market: Trends

Figure 7: Global Coronary Artery Bypass Grafts Market: Opportunity

Figure 8: Global Coronary Artery Bypass Grafts Market: Restraint

Figure 9: Global Coronary Artery Bypass Grafts Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Coronary Artery Bypass Grafts Market Value (USD Million) By Region

Figure 15: Global Coronary Artery Bypass Grafts Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Coronary Artery Bypass Grafts Market Value (USD Million) By Region

Figure 23: Global Coronary Artery Bypass Grafts Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Coronary Artery Bypass Grafts Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Coronary Artery Bypass Grafts Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Coronary Artery Bypass Grafts Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Coronary Artery Bypass Grafts Market Value (USD Million) By Region

Table 10: Global Coronary Artery Bypass Grafts Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Coronary Artery Bypass Grafts Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Coronary Artery Bypass Grafts Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Coronary Artery Bypass Grafts Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: MAQUET Basic Information And Sales Area

Table 33: MAQUET. Products Portfolio

Table 34: Medtronic Basic Information And Sales Area

Table 35: Medtronic. Products Portfolio

Table 36: Terumo Medical Basic Information And Sales Area

Table 37: Terumo Medical. Products Portfolio

Table 38: Boston Scientific Basic Information And Sales Area

Table 39: Boston Scientific. Products Portfolio

Table 40: Dextera Surgical Basic Information And Sales Area

Table 41: Dextera Surgical. Products Portfolio

Table 42: Edwards Lifesciences Basic Information And Sales Area

Table 43: Edwards Lifesciences. Products Portfolio

Table 44: Genesee BioMedical Basic Information And Sales Area

Table 45: Genesee BioMedical. Products Portfolio

Table 46: Hancock Jaffe Laboratories Basic Information And Sales Area

Table 47: Hancock Jaffe Laboratories. Products Portfolio

Table 48: HeartWare Basic Information And Sales Area

Table 49: HeartWare. Products Portfolio

Table 50: LivaNova Basic Information And Sales Area

Table 51: LivaNova. Products Portfolio

Table 52: Neograft Basic Information And Sales Area

Table 53: Neograft. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Coronary Artery Bypass Grafts Market Value (USD Million) By Region

Table 59: Global Coronary Artery Bypass Grafts Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Coronary Artery Bypass Grafts market size?

The Coronary Artery Bypass Grafts market size was estimated at roughly USD 1.3 billion in 2023, reflecting combined revenues from autologous vein, arterial and synthetic grafts worldwide. This baseline measurement underpins subsequent growth projections and investment analyses.

2. What is the projected growth forecast for the market through 2032?

Forecasts indicate the market will expand at a compound annual growth rate of 5.8 % from 2024 to 2032, reaching approximately USD 2.1 billion by the end of the period. This trajectory is driven by aging populations and rising cardiovascular disease prevalence.

3. Which factors are driving demand for coronary artery bypass grafts?

Key drivers include increasing incidence of coronary artery disease, expanding cardiac surgery volumes, and improvements in graft durability that boost surgeon confidence. Additionally, reimbursement reforms in major economies and heightened awareness of minimally invasive procedures are accelerating product adoption.

4. What challenges could impede market expansion?

Challenges stem from limited donor vessel availability, competition from percutaneous coronary interventions, and high procedural costs in low‑income markets. Regulatory uncertainties around novel synthetic grafts and the need for long‑term clinical data also constrain broader market penetration.

5. Which regions lead the Coronary Artery Bypass Grafts market and why?

North America remains the regional leader, driven by advanced healthcare infrastructure and high procedure rates, while Europe follows with strong public‑private partnerships. The Asia‑Pacific region shows the fastest growth, propelled by expanding middle‑class populations and increasing cardiac surgery capacity.

6. Who are the top companies competing in this space?

Top competitors include Medtronic, Abbott Laboratories, B. Braun, Terumo Corporation, and LivaNova, each offering a mix of autologous and synthetic graft solutions. These firms differentiate through R&D pipelines, strategic acquisitions, and extensive distribution networks across high‑value markets.

7. What future opportunities are emerging for product developers?

Future opportunities arise from personalized graft engineering, bio‑resorbable scaffolds, and integration with drug‑eluting technologies. Partnerships with biotech firms to develop endothelial‑cell‑seeded grafts and leveraging AI for patient‑specific graft selection are expected to unlock new revenue streams.

8. How are emerging technologies influencing graft performance and adoption?

Emerging technologies such as nanocoated surfaces, 3‑D printed vascular conduits, and gene‑edited endothelial layers are enhancing graft patency and reducing restenosis. These innovations also shorten operative times, potentially shifting surgeon preference toward advanced graft options.

9. What regulatory trends are shaping the market’s future outlook?

Regulatory landscape is evolving with accelerated pathways for bioengineered grafts in the US FDA’s Breakthrough Devices Program and the EU’s MDR classification updates. Compliance demands robust clinical evidence, yet streamlined approvals are shaping a more favorable future outlook for innovators.

Contact for Full Report

Loading report content...

Which Companies Lead the Coronary Artery Bypass Grafts Market in 2026?

Market Snapshot

Coronary Artery Bypass Grafts Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Coronary Artery Bypass Grafts Segmentation

Coronary Artery Bypass Grafts Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Coronary Artery Bypass Grafts market size?

2. What is the projected growth forecast for the market through 2032?

3. Which factors are driving demand for coronary artery bypass grafts?

4. What challenges could impede market expansion?

5. Which regions lead the Coronary Artery Bypass Grafts market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for product developers?

8. How are emerging technologies influencing graft performance and adoption?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Coronary Artery Bypass Grafts Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Coronary Artery Bypass Grafts Segmentation

Coronary Artery Bypass Grafts Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Coronary Artery Bypass Grafts market size?

2. What is the projected growth forecast for the market through 2032?

3. Which factors are driving demand for coronary artery bypass grafts?

4. What challenges could impede market expansion?

5. Which regions lead the Coronary Artery Bypass Grafts market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for product developers?

8. How are emerging technologies influencing graft performance and adoption?

9. What regulatory trends are shaping the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation